Showing 2131-2140 of 5771 results for "".
- Alimera Sciences Pre-Announces Expected Topline Revenue for Q1 2020 and Provides COVID-19 Business Updatehttps://modernod.com/news/alimera-sciences-pre-announces-expected-topline-revenue-for-q1-2020-and-provides-covid-19-business-update/2477586/Alimera Sciences announced topline revenue guidance for the quarter ending March 31, 2020. Alimera expects to report consolidated net revenue for the first quarter of 2020 exceeding $14 million, which compares to $12.9 million in the first quarter of 2019. Additionally, the company strengthened i
- GenSight Biologics Announces Positive Safety Review of PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Treatmenthttps://modernod.com/news/gensight-biologics-announces-positive-safety-review-of-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-treatment/2477583/GenSight Biologics announced that the independent Data Safety Monitoring Board (DSMB) completed its second planned safety review of the ongoing PIONEER phase 1/2 clinical trial of GS030, GenSight’s novel product combining gene therapy and optogenetics for the treatment of retinitis pigmentosa (RP
- Ophthalmic Companies Announce Changes to Operations and Guidancehttps://modernod.com/news/ophthalmic-companies-announce-chances-to-operations-and-guidance/2477582/The COVID-19 pandemic has caused several ophthalmic businesses to announce major changes to operations and guidance. Here is a review of some of the recent updates announced from publicly traded companies in the ophthalmology industry as a result of the pandemic. Alcon
- Bausch + Lomb Announces Publication Of 10-Year Armor Study Results On Ocular Antibiotic Resistancehttps://modernod.com/news/bausch-lomb-announces-publication-of-10-year-armor-study-results-on-ocular-antibiotic-resistance/2477577/Bausch + Lomb announced that JAMA Ophthalmology has
- AMA Suspends Plans for Annual Meeting in Chicagohttps://modernod.com/news/ama-suspends-plans-for-annual-meeting-in-chicago/2479528/The American Medical Association’s 2020 Annual Meeting planned for June in Chicago has been suspended due to the COVID-19 pandemic, according to a FierceHealthcare report. The AMA s
- BlephEx Announces Appeal Victory In Patent Litigation With Myco Industrieshttps://modernod.com/news/blephex-announces-appeal-victory-in-patent-litigation-with-myco-industries/2479532/BlephEx, creator of the BlephEx device and eyelid cleaning procedure, announced a victory before the Court of Appeals for the Federal Circuit in its ongoing patent litigation with Myco Industries
- Iveric bio Announces Fast Track Designation From FDA for Zimura for Treatment of Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/iveric-bio-announces-fast-track-designation-from-fda-for-zimura-for-treatment-of-geographic-atrophy-secondary-to-dry-amd/2477528/Iveric bio announced that the FDA has granted Fast Track designation to Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Currently, there is no FDA or EMA appro
- Vision Expo Announces Virtual Connections Program to Launch in Mid-Aprilhttps://modernod.com/news/vision-expo-announces-virtual-connections-program-to-launch-in-mid-april/2477509/Vision Expo has announced it will launch Virtual Connections, a new program designed to encourage and facilitate conversations and virtual meetings for Vision Expo East 2020 exhibitors and attendees who had registered for the event that was postponed as a result of COVID-19, according to a Vision
- Second Sight Announces Employee Layoffs, Intent to Wind Down Operationshttps://modernod.com/news/second-sight-announces-employee-layoffs-intent-to-wind-down-operations/2477503/Implantable visual prosthetics maker Second Sight Medical Products, announced that in response to the impact of the global COVID-19 pandemic on its ability to secure financing, the company decided to pursue an ord
- ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Updatehttps://modernod.com/news/proqr-announces-positive-findings-from-an-interim-analysis-in-the-phase-1-2-trial-of-qr-421a-for-usher-syndrome-and-provides-business-update/2477500/ProQR Therapeutics announced positive findings from a planned 3-month interim analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. The company is also providing an update